Literature DB >> 12707351

CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.

Daniela Verthelyi1, Mayda Gursel, Richard T Kenney, Jeffrey D Lifson, Shuying Liu, Joan Mican, Dennis M Klinman.   

Abstract

Oligodeoxynucleotides containing CpG motifs (CpG ODNs) mimic microbial DNA and activate effectors of the innate immune response, which limits the spread of pathogens and promotes an adaptive immune response. CpG ODNs have been shown to protect mice from infection with intracellular pathogens. Unfortunately, CpG motifs that optimally stimulate humans are only weakly active in mice, mandating the use of nonhuman primates to monitor the activity and safety of "human" CpG ODNs in vivo. This study demonstrates that CpG ODN treatment of rhesus macaques significantly reduces the severity of the lesions caused by a challenge with Leishmania: Leishmania superinfection is common in immunocompromised hosts, particularly those infected with HIV. This study shows that PBMCs from HIV-infected subjects respond to stimulation with CpG ODNs. To determine whether CpG ODNs can protect retrovirus-infected primates, SIV-infected macaques were treated with CpG ODNs and then challenged with Leishmania: Both lesion size and parasite load were significantly reduced in the CpG-treated animals. These findings support the clinical development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707351     DOI: 10.4049/jimmunol.170.9.4717

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  CpG oligodeoxynucleotides increase the susceptibility of normal mice to infection by Candida albicans.

Authors:  Shuichi Ito; Joao Pedras-Vasconcelos; Dennis M Klinman
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.

Authors:  Barbara Flynn; Vivian Wang; David L Sacks; Robert A Seder; Daniela Verthelyi
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques.

Authors:  Yichuan Wang; Kristina Abel; Katherine Lantz; Arthur M Krieg; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Impaired monocyte maturation in response to CpG oligodeoxynucleotide is related to viral RNA levels in human immunodeficiency virus disease and is at least partially mediated by deficiencies in alpha/beta interferon responsiveness and production.

Authors:  Wei Jiang; Michael M Lederman; Janelle R Salkowitz; Benigno Rodriguez; Clifford V Harding; Scott F Sieg
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 5.  CpG DNA as a vaccine adjuvant.

Authors:  Christian Bode; Gan Zhao; Folkert Steinhagen; Takeshi Kinjo; Dennis M Klinman
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

6.  Short- and long-term changes in gene expression mediated by the activation of TLR9.

Authors:  Sven Klaschik; Debra Tross; Hidekazu Shirota; Dennis M Klinman
Journal:  Mol Immunol       Date:  2009-12-14       Impact factor: 4.407

7.  Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques.

Authors:  V Ann Stewart; Shannon McGrath; Arthur M Krieg; Noelle S Larson; Evelina Angov; Christopher L Smith; Thomas G Brewer; D Gray Heppner
Journal:  Clin Vaccine Immunol       Date:  2007-12-12

8.  A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei.

Authors:  David M Waag; Michael J McCluskie; Ningli Zhang; Arthur M Krieg
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

9.  Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile.

Authors:  Györgyi Műzes; Ferenc Sipos; István Fűri; Miklós Constantinovits; Sándor Spisák; Barnabás Wichmann; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  Dig Dis Sci       Date:  2014-09-13       Impact factor: 3.199

10.  CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Authors:  Sanjai Kumar; Trevor R Jones; Miranda S Oakley; Hong Zheng; Shanmuga P Kuppusamy; Alem Taye; Arthur M Krieg; Anthony W Stowers; David C Kaslow; Stephen L Hoffman
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.